6.
Carla M, Savastano M, Boselli F, Giannuzzi F, Rizzo S
. Ranibizumab Port Delivery System in Neovascular Age-Related Macular Degeneration: Where Do We Stand? Overview of Pharmacokinetics, Clinical Results, and Future Directions. Pharmaceutics. 2024; 16(3).
PMC: 10974226.
DOI: 10.3390/pharmaceutics16030314.
View
7.
Claessen H, Kvitkina T, Narres M, Trautner C, Bertram B, Icks A
. Markedly decreasing incidence of cause-specific blindness in Saxony (Eastern Germany). Graefes Arch Clin Exp Ophthalmol. 2020; 259(5):1089-1101.
DOI: 10.1007/s00417-020-04885-4.
View
8.
Ehlken C, Helms M, Bohringer D, Agostini H, Stahl A
. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018; 12:13-20.
PMC: 5745150.
DOI: 10.2147/OPTH.S151611.
View
9.
Ehlken C, Wilke T, Bauer-Steinhusen U, Agostini H, Hasanbasic Z, Muller S
. TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE: Identification of Health Care Constraints in Germany-The PONS Study. Retina. 2017; 38(6):1134-1144.
DOI: 10.1097/IAE.0000000000001681.
View
10.
Figueras-Roca M, Parrado-Carrillo A, Nguyen V, Casaroli-Marano R, Moll-Udina A, Gillies M
. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefes Arch Clin Exp Ophthalmol. 2020; 259(6):1463-1470.
DOI: 10.1007/s00417-020-05016-9.
View
11.
Fuhrmann L, Bohringer D, Gass P, Dicke C, Eter N, Schargus M
. [Current situation of electronic medical records in ophthalmological departments in Germany]. Ophthalmologie. 2022; 119(8):827-833.
DOI: 10.1007/s00347-022-01605-7.
View
12.
Grzybowski A, Brona P
. Approval and Certification of Ophthalmic AI Devices in the European Union. Ophthalmol Ther. 2023; 12(2):633-638.
PMC: 10011240.
DOI: 10.1007/s40123-023-00652-w.
View
13.
Helotera H, Siintamo L, Kivinen N, Abrahamsson N, Aaltonen V, Kaarniranta K
. Analysis of prognostic and predictive factors in neovascular age-related macular degeneration Kuopio cohort. Acta Ophthalmol. 2024; 102(6):703-713.
DOI: 10.1111/aos.16681.
View
14.
Sagong M, Kim J, Woo S, Kim Y, Cho H, Lee Y
. Predictors of Disease Activity After Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration Using Real-World Data from the PROOF Study. Ophthalmol Ther. 2024; 13(11):2839-2853.
PMC: 11493875.
DOI: 10.1007/s40123-024-01021-x.
View
15.
Ma H, Wei H, Zou C, Zhu G, Gao Q, Zhang N
. Anti-VEGF Drugs in Age-Related Macular Degeneration: A Focus on Dosing Regimen-Related Safety and Efficacy. Drugs Aging. 2023; 40(11):991-1007.
DOI: 10.1007/s40266-023-01068-8.
View
16.
Hoffmann L, Runkel C, Kunzel S, Kabiri P, Rubsam A, Bonaventura T
. Using Deep Learning to Distinguish Highly Malignant Uveal Melanoma from Benign Choroidal Nevi. J Clin Med. 2024; 13(14).
PMC: 11277885.
DOI: 10.3390/jcm13144141.
View
17.
Schuster A, Wolfram C, Pfeiffer N, Finger R
. [Ophthalmology 2019-where do we stand? : An analysis of the treatment situation in Germany]. Ophthalmologe. 2019; 116(9):829-837.
DOI: 10.1007/s00347-019-0894-2.
View
18.
Semler S, Wissing F, Heyder R
. German Medical Informatics Initiative. Methods Inf Med. 2018; 57(S 01):e50-e56.
PMC: 6178199.
DOI: 10.3414/ME18-03-0003.
View
19.
Storp J, Dicke C, Bohringer D, Schargus M, Eter N
. [oregis-The German ophthalmological registry]. Ophthalmologie. 2023; 120(7):717-725.
DOI: 10.1007/s00347-022-01804-2.
View
20.
Volkmann I, Knoll K, Wiezorrek M, Greb O, Framme C
. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence. BMC Ophthalmol. 2020; 20(1):122.
PMC: 7104494.
DOI: 10.1186/s12886-020-01397-x.
View